<DOC>
	<DOCNO>NCT01336010</DOCNO>
	<brief_summary>To determine whether response guide treatment pegylated interferon +/- ribavirin effective treatment recently acquire hepatitis C infection . Response guide treatment length treatment determine quickly respond treatment .</brief_summary>
	<brief_title>Treatment Recently Acquired Hepatitis C Virus Infection</brief_title>
	<detailed_description>A prospective longitudinal study natural history treatment outcomes follow response guide treatment recent hepatitis C infection .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female patient ≥ 16 year age Recent hepatitis C infection estimate duration Infection ≤ 18 month define A ) ) First antiHCV antibody HCV RNA positive within previous 6 month ii ) Documented antiHCV antibody negative HCV RNA negative within 24 month prior antiHCV antibody positive result OR B ) ) First antiHCV antibody HCV RNA positive within previous 6 month ii ) acute clinical hepatitis ( jaundice ALT &gt; 10 X ULN ) within 12 month prior first positive HCV antibody HCV RNA cause acute hepatitis identifiable Adequate English provide write , informed consent provide reliable response study interview Provision write , informed consent . All patient : • Individuals consider study investigator unlikely participate intensive followup and/or unwilling provide extra blood sample Treatment group : Age 16 18 year Women ongoing pregnancy breast feed Therapy systemic antiviral , antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) *6 month prior first dose study drug Any investigational drug &lt; 6 week prior first dose study drug Positive test screen antiHAV IgM Ab , antiHBc IgM Ab History evidence medical condition associate chronic liver disease HCV ( e.g . hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) History evidence bleed esophageal varix condition consistent decompensated liver disease Neutrophil count &lt; 1500 cells/mm3 platelet count &lt; 90,000 cells/mm3 screen Serum creatinine level &gt; 1.5 time upper limit normal screen Hgb &lt; 12g/dL woman &lt; 13g/dL men screen ( patient receive combination therapy PEGIFN ribavirin ) Male partner woman pregnant ( patient receive combination therapy PEGIFN ribavirin ) History severe seizure disorder current anticonvulsant use History immunologically mediate disease , chronic pulmonary disease associate functional limitation , severe cardiac disease , major organ transplantation evidence severe illness , malignancy , condition would make patient , opinion investigator , unsuitable study History thyroid disease poorly control prescribed medication , elevate thyroid stimulate hormone ( TSH ) concentration elevation antibody thyroid peroxidase clinical manifestation thyroid disease Evidence severe retinopathy ( e.g . CMV retinitis , macular degeneration )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Acute Hepatitis C</keyword>
	<keyword>Early chronic Hepatitis C</keyword>
</DOC>